Precision by design: engineering site‑specific ADCs with machine learning

“ML is a genuine superpower for navigating large biochemical spaces, and it would be wrong to dismiss it. It is a multiplier for your data, not a replacement.”

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Weston Kightlinger, CEO, Ridge Bio, about the challenge of DAR heterogeneity and site specificity in ADC development, Ridge Bio’s ML–driven enzyme and linker engineering platforms, and what site–specific conjugation means for the future of ADCs as the field moves beyond oncology.

Please enter your email to access content Read now